Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intellia Thera CS (NQ: NTLA )

13.80 +0.68 (+5.18%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Thera CS

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Why Beam Therapeutics Jumped Today
A first for CRISPR-Cas9 might signal a new phase in the gene-editing revolution. 
Via The Motley Fool
Why Editas Medicine Stock Is Jumping Today
Good news for Intellia was viewed as good news for Editas. 
Via The Motley Fool
44 Stocks Moving In Monday's Mid-Day Session
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software... 
Via Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
Why Intellia Therapeutics Stock Is Skyrocketing Today
The company reported promising interim trial results for its CRISPR gene-editing candidate. 
Via The Motley Fool
Intellia Stock Leads Biotech Rally On Historic Moment For CRISPR
Intellia led a rally for CRISPR stocks on Monday on early promise for its gene-editing drug. The news sent NTLA stock to a record high. 
Via Investor's Business Daily
Stocks That Hit 52-Week Highs On Monday
During the morning session on Monday, 118 stocks hit new 52-week highs. Highlights: The company with the largest market cap to set a new 52-week high was Microsoft... 
Via Benzinga
Mid-Morning Market Update: Markets Mixed; Perion Network Boosts FY21 Outlook
Following the market opening Monday, the Dow traded down 0.30% to 34,329.01 while the NASDAQ rose 0.60% to 14,446.74. The S&P also rose, gaining 0.04% to 4,282.58. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Intellia Therapeutics Stock Is Soaring Today
Intellia Therapeutics Inc (NASDAQ:NTLA) is trading signifi... 
Via Benzinga
10 Biggest Price Target Changes For Monday
Barclays raised the price target for Accenture plc (NYSE: 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Intellia Therapeutics (NASDAQ:NTLA) stock rose 62.0% to $143.91 during Monday's pre-market session. The company's market cap stands at $9.8 billion.... 
Via Benzinga
Gene Editing Stocks: The Big News Lifting EDIT, BNGO, CRSP and NTLA Stocks
Gene editing stocks, led by NTLA stock, are powering higher on Monday following a landmark announcement by Intellia Therapeutics. 
Via InvestorPlace
24 Stocks Moving in Monday's Pre-Market Session
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) rose 28.9% to $114.49 in pre-market trading. Intellia Therapeutics and Regeneron Pharmaceuticals disclosed positive interim... 
Via Benzinga
Intellia Shares Shoot Higher On Promising Biomarker Data From CRISPR/Cas9 Genome Editing Candidate
Intellia Therapeutics Inc (NASDAQ: NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have announced positive interim data from an ongoing Phase 1... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Mixed; Crude Oil Edges Lower
Pre-open movers U.S. stock futures traded mixed in early pre-market trade after the Dow Jones surged more than 230 points in the previous session. The S&P 500 index also... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Expert Ratings For Intellia Therapeutics
Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 1 1... 
Via Benzinga
Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company
From Blackstone
Via Business Wire
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For June 11, 2021
Upgrades Barclays upgraded the previous rating for Ventas Inc (NYSE:VTR) from Equal-Weight to Overweight. In the first quarter, Ventas showed an EPS of $0.72, compared to... 
Via Benzinga
What's the Best Way to Invest in Genetics Stocks?
Here are some of our experts' favorite gene editing plays for the long run. 
Via The Motley Fool
This Genetics Stock Could Have a Bright Future
Here's one genetics play that you might want to put on your radar. 
Via The Motley Fool
Biotech Stocks Cruise Through The Volatility
The XLV Healthcare Select SPDR is up 10% YTD. 
Via Talk Markets
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
Intellia Therapeutics, Inc. (NTLA) Q1 2021 Earnings Call Transcript
NTLA earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Benzinga's Top Ratings Upgrades, Downgrades For May 7, 2021
Upgrades Loop Capital upgraded the previous rating for Roku Inc (NASDAQ:ROKU) from Hold to Buy. In the first quarter, Roku showed an EPS of $0.54, compared to $0.45 from... 
Via Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2021
Upgrades For Genuine Parts Co (NYSE:GPC), Goldman Sachs upgraded the previous rating of Sell to Neutral. In the first quarter, Genuine Parts showed an EPS of $1.50,... 
Via Benzinga
3 Exciting Biotech Stocks to Buy Right Now
Gene therapies could be poised to enter an era of extraordinarily rapid advancement. 
Via The Motley Fool
CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks Today
A "sell" rating is one thing, but a 50% price target? It's no wonder Editas stock is crashing, and taking other gene-editing stocks with it. 
Via InvestorPlace
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.